Novartis Bioventures Ltd
Insider
First SEC filing: March 19, 2014 · Latest: March 19, 2014
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs the latest weekly close (updated to the current quote in your browser when available), split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| March 25, 2014 | AKBA | P | 182,590 | $17.00 | $3,104,030 | 182,590 Direct | · | Acquired | -96.7% (price as of ) |
| March 25, 2014 | AKBA | C | 3,223,174 | · | · | 3,405,764 Direct | +1765.25% | Acquired | |
| March 25, 2014 | AKBA | C | 257,031 | · | · | 0 Direct | -100.00% | Disposed | |
| March 25, 2014 | AKBA | C | 347,831 | · | · | 0 Direct | -100.00% | Disposed | |
| March 25, 2014 | AKBA | C | 708,647 | · | · | 0 Direct | -100.00% | Disposed |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 25, 2014 | AKBA | Series A Convertible Preferred Stock | Common Stock | · | · | 257,031 | Disposed |
| March 25, 2014 | AKBA | Series B Convertible Preferred Stock | Common Stock | · | · | 347,831 | Disposed |
| March 25, 2014 | AKBA | Series C Convertible Preferred Stock | Common Stock | · | · | 708,647 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 3 holdings
Securities held when first becoming an insider, per SEC Form 3.